A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Jain, Varsha K ^a   Chandrasekaran, Vijayalakshmi ^a   Wang, Long ^a   Li, Ping ^a   Liu, Aixue ^a   Innis, Bruce L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adults; Inactivated; Influenza; Quadrivalent; Thimerosal containing; Trivalent

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; THIOMERSAL;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHEST TIGHTNESS; CHILL; COUGHING; DRUG MANUFACTURE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EYE REDNESS; FACE EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HOARSENESS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 3 CLINICAL TRIAL; SEROCONVERSION; SKIN REDNESS; SORE THROAT; VIRION; VIRUS STRAIN; ABDOMINAL PAIN; COLIC; CROHN DISEASE; DIARRHEA; DIZZINESS; HEMATOMA; INFECTION PREVENTION; INJECTION SITE BLEEDING; INJECTION SITE PARESTHESIA; NAUSEA; NEPHRITIS; PHASE 3 CLINICAL TRIAL (TOPIC); SEDATION; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; DRUG FORMULATION; EPIDEMIOLOGY; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; DRUG COMPOUNDING; FEMALE; HISTORICALLY CONTROLLED STUDY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; THIMEROSAL; YOUNG ADULT;

EID: 84899049970     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-133     Document Type: Article

References (27)

1. Li S, Leader S. Economic burden and absenteeism from influenza-like illness in healthy households with children (5-17 years) in the US. Respir Med 2007, 101(6):1244-1250. 10.1016/j.rmed.2006.10.022, 17156991.
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(27):5086-5096. 10.1016/j.vaccine.2007.03.046, 17544181.
3. Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis 2009, 48(3):292-298. 10.1086/595842, 19115970.
4. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357(14):1373-1381. 10.1056/NEJMoa070844, 17914038.
5. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340. 10.1001/jama.292.11.1333, 15367555.
6. Advisory Committee on Immunization Practices CDC's Advisory Committee on Immunization Practices (ACIP) Recommends Universal Annual Influenza Vaccination. 2010, Press Release; http://www.cdc.gov/media/pressrel/2010/r100224.htm. [Accessed 11 October 2013], Advisory Committee on Immunization Practices.
7. United States Centers for Disease Control and Prevention Seasonal influenza activity surveillance reports: 2000-2001 to 2010-2011 seasons. http://www.cdc.gov/flu/weekly/pastreports.htm. [Accessed 11 October 2013], United States Centers for Disease Control and Prevention.
8. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Zhang W, WHO Writing Group Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 2012, 6(2):142-152. e141-145, WHO Writing Group.
9. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199(2):159-167. 10.1086/595861, 19086915.
10. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28(9):2149-2156. 10.1016/j.vaccine.2009.11.068, 20003926.
11. Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, Chen CH, Huang HH, Chang CH, Chou JH, Chang FY, Lin TY, Chiu WT. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season. PLoS ONE 2013, 8(3):e58222. 10.1371/journal.pone.0058222, 3589334, 23472161.
12. World Health Organization Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. 2012, http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf. [Accessed 11 October 2013], World Health Organization.
13. Fluarix™ Quadrivalent (influenza virus vaccine) Prescribing Information. GlaxoSmithKline Biologicals, Rixensart, Belgium. 2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf. [Accessed 2 January 2014], Fluarix™ Quadrivalent (influenza virus vaccine).
14. Flulaval™ Quadrivalent (influenza virus vaccine) Prescribing Information. GlaxoSmithKline, Research Triangle Park, NC 27709, USA. 2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM366070.pdf. [Accessed 2 January 2014], Flulaval™ Quadrivalent (influenza virus vaccine).
15. Flumist® Quadrivalent (Influenza Vaccine Live I Prescribing Information. MedImmune LLC, Gaithersburg, MD 20878, USA. 2013, http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm293952.htm. [Accessed 2 January 2014], Flumist® Quadrivalent (Influenza Vaccine Live I.
16. Fluzone™ Quadrivalent (influenza virus vaccine) Prescribing Information. Sanofi Pasteur Inc. 1 Swiftwater, PA 18370, USA. 2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM356094.pdf. [Accessed 2 January 2014], Fluzone™ Quadrivalent (influenza virus vaccine).
17. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, De la Cueva S, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la OM, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013, 208(4):544-553. 10.1093/infdis/jit263, 3719910, 23847058.
18. Tinoco C, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis B, Jain V. Immunogenicity, reactogenicity, and safety of quadrivalent inactivated influenza vaccine versus trivalent inactivated influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine 2013, In press.
19. World Health Organization Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012 - conclusions and recommendations. Information on vaccines for an Intergovernmental Negotiating Committee to prepare a global legally binding instrument on the use of mercury. Wkly Epidemiol Rec 2012, 21(87):201-216. World Health Organization.
20. Hehme N, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig 2002, 22(11):751-769.
21. The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Note for guidance on harmonization of requirements for influenza vaccines CPMP/BWP/214/96 1997. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf. [Accessed 11 October 2013], The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products.
22. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994, 12(13):1185-1189. 10.1016/0264-410X(94)90241-0, 7839722.
23. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272(21):1661-1665. 10.1001/jama.1994.03520210045030, 7966893.
24. Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology 2007, 53(6):411-418.
25. Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007, 79(3):320-325. 10.1002/jmv.20801, 17245715.
26. Pyhala R, Kumpulainen V, Alanko S, Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994, 12(10):947-952. 10.1016/0264-410X(94)90039-6, 7975836.
27. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, Innis BL. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 2005, 1(6):239-244. 10.4161/hv.1.6.2376, 17012883.